Amy is an Associate Director at AstraZeneca, she joined the Genetic Toxicology team at as Senior Scientist in 2016 and is responsible for providing non-clinical safety assessment and mechanistic Genetic toxicology investigations for projects across the development pipeline.

Following her undergraduate studies at University of Liverpool, which included an industrial placement within AstraZeneca, Amy went on to complete her PhD studies at Kings College, London, focussing on identifying novel proteins involved in cytokinesis.

Amy has an interest in the development and application of innovative multi-disciplinary approaches for genetic toxicology assessment and has expertise in high content imaging, data analysis approaches and machine learning applications to improve in vitro-in vivo translation and provide greater insights into the mechanisms of toxicity.

Amy is currently chair of the Industrial Genotoxicology Group (IGG) and participates in several international external initiatives to advance the field of genetic toxicology, she is keen to promote cross-industry and academic collaborations and is passionate about the development of new investigators within the field and encouraging the growth and development of other early career scientists.